Business Context and Reporting Period
This Form 8-K filing by BioXcel Therapeutics, Inc. (BTAI) reports on events occurring on July 31, 2026. The Company, incorporated in Delaware and listed on the Nasdaq Capital Market, entered into a material definitive agreement regarding its existing credit facilities.
Key Financial Metrics and Debt
- Debt Obligation: The Company has a principal and interest payment of $9,016,914.47 originally due on June 30, 2026.
- Liquidity Covenant: The minimum cash liquidity requirement under the Credit Agreement was reduced from $7.5 million to $6.25 million.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins.
Material Changes and Agreement Terms
The Company executed the Eleventh Amendment to Credit Agreement and Guaranty with its lenders and Oaktree Fund Administration LLC. Key changes include:
- Payment Deferral: The payment of $9,016,914.47 (plus accrued interest and fees through August 31, 2026) has been deferred from July 31, 2026, to August 31, 2026.
- Covenant Adjustment: The minimum liquidity covenant threshold was lowered to $6.25 million.
- Transaction Deadline: The Company must enter into definitive agreements for loan repayment or alternative capital solutions by August 10, 2026 (extended from July 31, 2026).
- Compensation Restrictions: Until August 10, 2026, the Company is prohibited from modifying compensation arrangements for directors, officers, or employees or making non-ordinary course payments to them.
Outlook, Risks, and Contingencies
The filing highlights a critical contingency: the Company must secure a transaction acceptable to lenders by August 10, 2026, to repay obligations or restructure capital. Failure to meet this deadline or the August 31, 2026 payment obligation could result in default. The text does not provide specific management commentary on future revenue guidance or operational outlook beyond these debt-related constraints.
Investor Verification Checklist
- Verify the Company's ability to secure a repayment or capital solution transaction by the August 10, 2026 deadline.
- Confirm the Company's cash position relative to the new $6.25 million minimum liquidity covenant.
- Monitor the status of the $9.02 million payment due on August 31, 2026.
- Review the full text of the Eleventh Amendment (Exhibit 10.1) for additional covenants or conditions not summarized in this report.